O-31 a Boy With Sickle Cell Anemia Appears to Be O RHD Positive but Should Receive O RHD Negative for His Red Cell Exchange Therapy

Witt, Volker; Beiglböck, E.; Wurth, Mark; Ritter, R.; Jungbauer, Christof

doi:10.1016/s1473-0502(12)70032-0

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most alloimmunized patients with SCD will not have serious complications of alloimmunization . However, patients with SCD are at high risk for DHTRs (including life‐threatening events) . For example, Vidler and colleagues reported that almost 8% of SCD patients who received transfusions developed DHTRs over a 5‐year period .…”

Section: Resultsmentioning

confidence: 99%

“…14,60,61 However, patients with SCD are at high risk for DHTRs (including life-threatening events). 12,[62][63][64][65][66][67][68][69][70][71] For example, Vidler and colleagues reported that almost 8% of SCD patients who received transfusions developed DHTRs over a 5-year period. 12 Several reports show that many episodes of DHTR are initially misdiagnosed as vaso-occlusive pain crisis.…”

Section: What Are the Risk Factors For Alloimmunization In The Scd Pomentioning

confidence: 99%

See 1 more Smart Citation

Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease

et al. 2017

View full text Add to dashboard Cite

BACKGROUND The pathogenesis of alloimmunization is not well understood, and initiatives that aim to reduce the incidence of alloimmunization are generally expensive and either ineffective or unproven. In this review, we summarize the current medical literature regarding alloimmunization in the sickle cell disease (SCD) population, with a special focus on the financial implications of different approaches to prevent alloimmunization. STUDY DESIGN AND METHODS A review of EMBASE and MEDLINE data from January 2006 through January 2016 was conducted to identify articles relating to complications of SCD. The search was specifically designed to capture articles that evaluated the costs of various strategies to prevent alloimmunization and its sequelae. RESULTS Currently, there is no proven, inexpensive way to prevent alloimmunization among individuals with SCD. Serologic matching programs are not uniformly successful in preventing alloimmunization, particularly to Rh antigens, because of the high frequency of variant Rh alleles in the SCD population. A genotypic matching program could offer some cost savings compared to a serologic matching program, but the efficacy of gene matching for the prevention of alloimmunization is largely unproven, and large-scale implementation could be expensive. CONCLUSIONS Future reductions in the costs associated with genotype matching could make a large-scale program economically feasible. Novel techniques to identify patients at highest risk for alloimmunization could improve the cost effectiveness of antigen matching programs. A clinical trial comparing the efficacy of serologic matching to genotype matching would be informative.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: What Are the Risk Factors For Alloimmunization In The Scd Pomentioning

confidence: 99%

Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease

et al. 2017

View full text Add to dashboard Cite

show abstract

O-31 a Boy With Sickle Cell Anemia Appears to Be O RHD Positive but Should Receive O RHD Negative for His Red Cell Exchange Therapy

Cited by 1 publication

References 0 publications

Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease

Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease

Contact Info

Product

Resources

About